News Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Real-time Estimate Cboe BZX Other stock markets 01:15:30 2024-04-16 pm EDT			5-day change	1st Jan Change
5.185 ^USD	-3.08%		-11.06%	+19.75%

Mar. 20	Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	MT
Mar. 20	Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	CI

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(4)	Apr. 04	AQ
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	Apr. 03	BU
Puma Biotechnology Plans to Start Breast Cancer Combination Study in Second Half; Shares Rise	Mar. 20	MT
Puma Biotechnology Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Mar. 20	BU
Puma Biotechnology, Inc. Announces FDA Allowance to Proceed Under IND for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Mar. 20	CI
Puma Biotechnology : Corporate Presentation	Mar. 06	PU
Puma Biotech: Q4 Earnings Snapshot	Feb. 29	AQ
Puma Biotechnology, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Transcript : Puma Biotechnology, Inc., Q4 2023 Earnings Call, Feb 29, 2024	Feb. 29
Puma Biotechnology, Inc. Provides Earnings Guidance for the First Quarter and Full Year of 2024	Feb. 29	CI
Puma Biotechnology Reports Fourth Quarter and Full Year 2023 Financial Results	Feb. 29	BU
Earnings Flash (PBYI) PUMA BIOTECHNOLOGY Posts Q4 EPS $0.31, vs. Street Est of $0.37	Feb. 29	MT
Puma Biotechnology, Inc. Reports Earnings Results for the Fourth Quarter Ended December 31, 2023	Feb. 29	CI
Puma Biotechnology Reports Inducement Awards Under Nasdaq Listing Rule 5635(c)(4)	Feb. 27	BU
Puma Biotechnology to Participate in a Panel Discussion at TD Cowen’s 44th Annual Health Care Conference	Feb. 22	BU
Puma Biotechnology to Host Conference Call to Discuss Fourth Quarter and Full Year 2023 Financial Results	Feb. 15	BU
Puma Biotechnology Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	Feb. 13	BU
Puma Biotechnology, Inc. Announces Initiation of ALISCA-Lung1 Phase II Trial of Alisertib in Small Cell Lung Cancer	Feb. 13	CI
Puma Biotechnology to Present at B. Riley Securities 4th Annual Oncology Conference	Jan. 11	BU
Puma Biotechnology Announces Phase II Clinical Trial Design for Alisertib in HER2-Negative, Hormone Receptor-Positive Metastatic Breast Cancer	Dec. 11	BU

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Puma Biotechnology, Inc.

Equities

PBYI

US74587V1070

Summary

Filters